Phase 1 data for SRSD216, a novel siRNA targeting human LPA mRNA, suggest dose dependent and durable Lp(a) lowering, with good tolerability. Single subcutaneous doses of SRSD216 (100 mg, 300 mg, 600 mg) or placebo were administered to three cohorts of eight individuals with Lp(a) levels ≥75 nmol/L.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
